Merck acquired VXRT Inc., a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, for USD 3.2 billion. The acquisition strengthened Merck's vaccine pipeline and added new vaccine candidates for COVID-19 and other infectious diseases.
Merck acquired Peloton Therapeutics, Inc., a clinical-stage biotechnology company developing novel therapies for the treatment of cancer, for USD 1.1 billion. The acquisition added several new cancer therapy candidates to Merck's pipeline, including PT-101, a small molecule inhibitor of DDR1, and PT-102, a small molecule inhibitor of MTAP.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5402
Published Date: Nov 27, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing demand from healthcare sector is the major factor driving the market growth.
The market size of pyomyositis is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2024-2036.
The major players in the market Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline (GSK), Novartis International AG, Sanofi S.A., Johnson & Johnson, and others.
The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.